A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

← catalyst calendar

NCT07690371 · readout ≤ 651 d

Sponsored by Nektar Therapeutics (industry) · NKTR — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

510estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-29

actual

When the study began enrolling

Primary completion

May 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2028

estimated

The whole study's end, after follow-up

First posted

2026-07-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Moderate-to-Severe Atopic Dermatitis

Interventions

Drug: Rezpegaldesleukin — also filed as NKTR-358
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24

measured Week 0 and Week 24

Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24

measured Week 0 and Week 24

Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75)

measured Week 0 and Week 24

Permalink · NKTR's whole pipeline · Catalyst calendar · Every registered study · What changed